Abstract E-cadherin is a major component of tubular adherent proteins that maintain intercellular contacts and cell polarity in epithelial tissue. It is involved in pathological processes of renal cell carcinoma and fibrotic diseases via epithelial-mesenchymal transition. Although studies have shown E-cadherin is significantly downregulated in acute kidney injury (AKI), its function in AKI is unknown. Here, we evaluated cell damage and inflammation in cisplatin-stimulated tubular epithelial cell lines after disrupting E-cadherin and restoring it with PPBICA, a small molecule identified by highthroughput screening. We also determined the therapeutic potential of restoring E-cadherin in vivo. Results show cisplatin reduced E-cadherin expression both in mouse kidney and proximal tubular epithelial cell lines (mTECs). PPBICA restored E-cadherin levels, which increased cell viability while attenuating programmed cell death. This may be mediated via deactivation of the RIPK1/RIPK3 axis and decreased caspase3 cleavage. In addition, PPBICA suppressed inflammatory response in cisplatin-treated mTECs, which correlated with suppressed NF-κB phosphorylation and promoter activity. In contrast, disruption of E-cadherin promoted cell damage and inflammation. PPBICA failed to further attenuate kidney damage in E-cadherin knockdown cells, indicating that PPBICA protects against mTECs through E-cadherin restoration. We also found that peritoneal injection of PPBICA in mice prevented loss of renal function and tubular damage by suppressing NF-κB-driven renal inflammation and RIPK-regulated programmed cell death. This was driven by restoration of E-cadherin in cisplatin nephropathy. Additionally, PPBICA attenuated cisplatin-induced kidney damage in an established AKI model, indicating its therapeutic potential in the treatment of AKI. In conclusion, E-cadherin plays functional roles in tubule integrity, programmed cell death, and renal inflammation. Our results underscore the potential of E-cadherin restoration as a novel therapeutic strategy for AKI.
Introduction
Acute kidney injury (AKI) is a significant clinical problem and correlated with high morbidity and mortality rates. Recent evidence has shown severe AKI causes abnormal cellular repair and fibrosis, leading to chronic diseases and end stage renal disease (ESRD). AKI is characterized by sudden decline in renal function over a short time period, and it is always induced by hemodynamic, hypoxic, mechanical, and toxic insults [1, 2] . Although programmed cell death and inflammation are believed to play roles in the pathophysiological process of AKI, a detailed mechanism and effective therapy are yet to be determined [3, 4] . Kidney epithelial cells communicate with each other via tight junctions, including major transmembrane proteins and zonular occludins, and adhesion junctions consisting of adherent proteins like E-cadherin [5] . Loss of integrity of renal parenchyma plays critical roles in damaged kidneys of AKI. Previous findings show pharmacological inhibition of Src kinase protects against AKI in a murine model of renal ischemia/reperfusion [6] . In response to this injury, dissociation of cellular junctions and loss of cell-to-cell interplay leads to back-leak of tubular fluid and inflammatory response. This further damages tubular epithelial and endothelial cell integrity in a toxic feedback loop [7] . Therefore, restoring tubule integrity should be considered as a therapeutic tool in AKI treatment.
E-cadherin is a major component of tubular adherent proteins and maintains intercellular contacts and cell polarity in epithelial tissue by regulating actin cytoskeleton [8] . As a calcium-dependent cell adhesion molecule, E-cadherin is a transmembrane protein belonging to the classical cadherin family and widely investigated in renal cell carcinoma (RCC) and renal fibrotic diseases [9, 10] . However, these lines of evidence focused on the importance of E-cadherin in epithelial-mesenchymal transition (EMT) in the progression of renal diseases. Our preliminary studies and recent data from other groups have consistently shown that E-cadherin levels are reduced in response to cisplatin in the acute phase of injury. Although we know pharmacological inhibition of Src kinase protects against renal ischemia/reperfusion-induced injury, partly through enhancing E-cadherin and claudins [6] , the exact function and detailed mechanism of E-cadherin in AKI are unknown. Thus, we used PPBICA, a small molecule identified by high-throughput screening, to enhance Ecadherin expression via histone deacetylase (HDAC)-independent mechanism. This technique is superior to HDAC inhibitor-mediated enhancement of E-cadherin, given its nonspecific side effects [8] . We disrupted E-cadherin and/or restored E-cadherin in cisplatin-treated tubular epithelial cells and an animal model of cisplatin nephropathy to measure the function and therapeutic potential in AKI.
Materials And methods

Model of Cisplatin-Induced AKI and Drug Treatment
Male C57/BL mice (Laboratory Animal Center, Anhui, China) were housed in constant temperature and humidity environment with a 12:12 h light-dark cycle. All animal procedures were approved by the Animal Experimentation Ethics Committee from Anhui Medical University, Anhui, China. Mice were divided into three groups randomly at 8 weeks age. A volume of 20 mg/kg Cisplatin (Sigma, Shanghai, China) or saline was given by a single intraperitoneal injection as previously described [2] . Our pilot study indicated that 25 mg/kg PPBICA effectively attenuated renal damage without showing nephrotoxicity in vivo, so this dosage of PPBICA was injected intraperitoneally once daily for four times from one day before cisplatin treatment. Mice were killed under anesthesia while kidney tissues and blood samples were collected for further experiments, including renal function, histology, and molecular analysis.
Reagents and materials
Antibodies RIPK1, RIPK3, β-actin, and OCT2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-E-cadherin, anti-P-P65 and anti-P65 were purchased from Cell Signaling Technology (CST, Danvers, 
Cell culture
MTECs (a mouse kidney proximal tubular epithelial cell line) was provided by prof. Hui Yao Lan from The Chinese University of Hong Kong as described [11] . E-cadherin was disrupted by transfection with sequence-specific shRNA or scramble control plasmid (GenePharma, Shanghai, China) by lipofectamine 2000 according to the instructions of manufacture. Cells with shRNA plasmid screened by puromycin were cultured in DMEM/F12 (HyCloneTM, USA), supplemented with 5% fetal bovine serum at 37°C in humidified 5% CO2. Then, E-cadherin was detected by western blot and realtime PCR to evaluate the knockdown efficiency. Cisplatin (20 µM), TNF-α, TNF-α + z-VAD, and/or PPBICA (1 µM) treated cells were harvested after twenty-four hours for further analysis, including cell viability, the indexes of kidney injury, programmed cell death, inflammatory response through western blot, real-time PCR, and flow cytometry (FCM) etc. Three to four in vitro experiments were performed independently.
Cell viability assay
Cell viability was tested by using Cell Counting MTT assays. MTECs were treated with a set of concentrations of PPBICA and/or cisplatin for 24 h before being exposed to MTT (5 mg/ml) solution for 4 h. At 492 nm wavelength, optical density (OD) detection was performed by microplate reader (Multiskan MK3, Thermo, USA).
RNA extraction and real-time PCR
Total RNA was extracted from kidney homogenate or mTECs using the RNeasy Isolation Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. NanoDrop 2000 Spectrophotometer (Thermo Scientific, USA) was applied for the quantitative RNA concentration and reverse-transcribed cDNA with RealMasterMix (TOYOBO, Japan). Then target gene expression was performed using THUNDERBIRD TM SYBR®Qpcr Mix (TOYOBO, Japan) and quantified using Real-Time Polymerase Chain Reaction (RT-PCR) Detection System (TOYOBO, Japan). The sequences of primers were previously reported or as follows [12, 13] . Mouse E-cadherin, forward 5′-CGACCGGAAGTGACTCGAAAT -3′, reverse 5′-TCAGAACCACTGCCCTCGTAAT -3′. The real-time PCR data were analyzed using the relative gene expression (2-ΔΔCt) method.
Western blot analysis
Proteins were separated from pulverized tissue or cells in ice-cold RIPA-Buffer (Beyotime, Jiangsu, China), whose concentration was quantified by BCA protein kit (Beyotime, Jiangsu, China). Proteins were Supplemented with 10% SDS-PAGE and transferred to nitrocellulose membranes. After blocking, membranes were incubated overnight at 4°C with the appropriate antibodies against KIM1, E-cadherin, P-P65, P65, RIPK1, RIPK3, Cleaved-caspase3, OCT2, and β-actin, and then incubated with IRDye 800-conjugated secondary antibody for 1.5 h at room temperature (1:10000, Rockland immunochemicals, Gilbertsville, PA). Membranes were detected by LiCor/Odyssey infrared image system (LI-COR Biosciences, Lincoln, NE) and quantified using the Image J software (NIH, Bethesda, MD, USA).
Immunofluorescence assay
For staining of E-cadherin, single-layer mTECs on cover slips were fixed by 4% parafomaldehyde for 10 min. After washing three times with PBS, the cells were blocked with 5% normal serum for 60 min at room temperature, and then labeled with appropriate antibody at 4°C overnight. Secondary antibodies (Bioss, Beijing, China) were added for 1 h in the dark at room temperature. The nucleus was marked with DAPI. After a final wash, sections were evaluated by Inverted Fluorescence Microscope (Olympus, Japan)
Flow cytometry
For assessing programmed cell death, attached and supernatant cells were stained with 5 µL Annexin V-FITC and 5 µL PI in the dark, performed on BD FACSVerse flow cytometer machine, quantified by FlowJo 7.6 software. Fig. 2 PPBICA restored E-cadherin expression and attenuated cisplatin-induced cell injury and inflammation in mTECs. a Immunofluorescence of E-cadherin in mTECs. b Western blot of E-cadherin in cisplatin-treated mTECs. PPBICA increased E-cadherin in cisplatinstimulated mTECs. c, d Western blot and real-time PCR of KIM1 in mTECs. PPBICA significantly reduced protein and mRNA levels of KIM1. e Real-time PCR shows PPBICA decreased cisplatinupregulated mRNA level of TNF-α, IL-1β, IL-6, and MCP-1 in mTECs. f, g Western blot and promoter assay of NF-κB. Data represent the mean ± SEM for 3-4 independent experiments. * * p < 0.01, * * * p < 0.001 compared with control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared with cisplatin-treated group. Cis cisplatin
Kidney histology
Kidney tissues were fixed (4% PFA), dehydrated, and embedded in paraffin. Tissue slides (4 µm thick) were stained with periodic acid-Schiff (PAS) to assess the degree of tubulointerstitial damage and subjected to relevant antibody to detect protein expression. PAS sections was scored using a previously described [2] . IHC sections were performed by a microwave-based antigen retrieval technique [14] , incubated with rabbit anti-KIM1, anti-TNF-α, anti-E-cadherin, and rabbit anti-F4/80 antibody for 24 h at 4°C and secondary antibodies for 30 min at 37°C. Followed by labeled with chromagen liquid DAB (3, 30-diaminobenzidine tetrahydrochloride), sections were photographed using a microscope (Olympus, Japan) at ×200 magnification. We took 10 consecutive pictures in each 
Statistical analysis
Data are expressed as the mean ± SE of the mean. Statistical significance was analyzed by two-tailed unpaired t-test or one-way analysis of variance (ANOVA), followed by Tukey post hoc tests using GraphPad Prism 5 software.
Results
PPBICA inhibited cisplatin-induced death of mTECs
We determine the impact of PPBICA on cell viability in a mice tubular epithelial cell line (mTEC) by MTT assay. Results show PPBICA concentrations no higher than 2 µM had limited inhibitory effect on the viability of normal TECs (Fig. 1b) . And, PPBICA restored cell viability in cisplatin-treated mTECs at a concentration of 1 µM (Fig. 1c) .
PPBICA restored E-cadherin expression and attenuated cisplatin-induced cell injury and inflammation
Immunofluorescence assay and western blot results show Ecadherin highly expressed in normal mTECs and significantly reduced after cisplatin treatment. Levels of Ecadherin were restored after PPBICA treatment (Fig. 2a, b) . We then measured expression of kidney injury molecule-1 (KIM1) and found PPBICA suppressed cisplatin-induced KIM1 protein and mRNA (Fig. 2c, d) . To measure the impact on inflammatory response, we analyzed common pathway cytokines. Results show PPBICA downregulated inflammatory cytokines TNF-α, IL-1β, IL-6, and chemokine MCP-1 (Fig. 2e) . These findings are supported by western blot and promoter assay results showing NF-κB activation (Fig. 2f, g ).
PPBICA attenuated cisplatin-induced programmed cell death in mTECs
We then determine PPBICA's effect on programmed cell death by using flow cytometric analysis. Results show PPBICA suppressed cisplatin-induced damage via E-cadherindependent mechanism a E-cadherin knockdown mTECs. Western blot and real-time PCR show E-cadherin downregulated after transfection of E-cadherin shRNA plasmid. c Western blot analysis of E-cadherin in cisplatin-treated mTECs. PPBICA had no significant impact on restoring E-cadherin expression in E-cadherin knockdown mTECs. d, e Western blot and real-time PCR analysis of KIM1 in E-cadherin knockdown mTECs. f Western blot analysis of P-P65 NF-κB. PPBICA failed to attenuate KIM1 expression and P65 NF-κB phosphorylation when E-cadherin was disrupted in cisplatin-treated mTECs. g Real-time PCR of inflammatory indexes. Knockdown of E-cadherin failed to further decrease inflammatory cytokine IL-1β and chemokine monocyte chemotactic protein (MCP-1) in cisplatin-treated mTECs. h. Promoter assay of NF-κB. Data represent the mean ± SEM for 3-4 independent experiments. * p < 0.05, * * p < 0.01, * * * p < 0.001 compared with control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared with E-cadherin EV group. $p < 0.05, $$p < 0.01 compared with cisplatin-treated group. Cis cisplatin, Control empty vector, E-cad-KD Knockdown of E-cadherin PPBICA reduced the percentage of necroptotic and apoptotic cells in response to cisplatin (Fig. 3a) . We then measured necroptosis using NEC-1, a necroptosis inhibitor that blocks RIPK1. After NEC-1 treatment, PPCIBA failed to further downregulate RIPK signaling and KIM1 expression in response to cisplatin (Fig. 3b) . Finally, PPBICA decreased cleaved-caspase3 in cisplatin-treated cells (Fig. 3c) . To further confirm the inhibitory effect of PPBICA, we established another in vitro model of necroptosis and apoptosis with TNF-α + z-VAD and TNF-α, respectively, western blot result indicates that PPBICA directly suppressed the RIPK signaling and caspase3 cleavage (Fig. 4) .
PPBICA suppressed cisplatin-induced damage via E-cadherin-dependent mechanism
To determine the role of PPBICA in mediating protective effects, we knocked down E-cadherin in mTEC cells and measured the outcome. We found that E-cadherin mRNA and protein significantly reduced in cisplatin-stimulated mTECs (Fig. 5a, b) . In addition, PPBICA had no significant effect on restoring E-cadherin (Fig. 5c) . Furthermore, PPBICA failed to further reduce cisplatin-induced KIM1 and NF-κB-mediated inflammatory response in E-cadherin deficient cells (Fig. 5d-h ). These findings indicate E-cadherin plays an important role in mediating the therapeutic effect of PPBICA.
PPBICA restored E-cadherin level and prevented cisplatin-induced acute kidney injury in mice
To better understand how PPBICA affects E-cadherin in cisplatin-treated mice, we measured E-cadherin levels using immunohistochemistry and western blot. Results showed E-cadherin level decreased in response to cisplatin injection, but were restored by PPBICA (Fig. 6a, b) . Additionally, PAS staining showed that cell swelling, cytoplasmic vacuolization, detached cell necrotic tubules, and cast formation were significantly reduced after PPBICA treatment (Fig. 6c) . PPBICA also improved renal function as measured by serum creatinine and BUN (Fig. 6d, e) . Western blot and IHC results show PPBICA reduced KIM1 protein level, which was supported by real-time PCR results showing lower mRNA levels (Fig. 6f-h) . Collectively, these data show PPBICA had a therapeutic effect on cisplatin nephropathy.
PPBICA ameliorated cisplatin-induced inflammatory response and programmed cell death in mice
Results from IHC staining show PPBICA significantly suppressed macrophage infiltration (Fig. 7a) . IHC staining and real-time PCR show PPBICA reduced TNF-α protein and mRNA levels, which align with the findings that PPBICA decreased mRNA levels of IL-6, IL-1β, and MCP-1 in cisplatin nephropathy (Fig. 7b, c) . Western blot data show PPBICA significantly reduced phosphorylation of p65 NF-κB (Fig. 8a) . And, PPBICA suppressed the necroptosiscorrelated RIPK1/RIPK3 signaling and apoptosis-correlated cleavage of caspase3 (Fig. 8b) . These findings highlight the protective effects of PPBICA on cisplatin-induced renal inflammation and programmed cell death in vivo.
PPBICA attenuated cisplatin-induced kidney injury in established AKI mouse model
To determine the therapeutic potential of PPBICA in an established AKI mouse model, we injected PPBICA one day after cisplatin injection. PAS staining shows PPBICA attenuated kidney damage (Fig. 9a) . This was further supported by results from serum creatinine and BUN assays and immunostaining of KIM1 (Fig. 9b-d) .
Discussion
In the current study, we provided novel evidence showing E-cadherin was significantly reduced in cells or kidney tissues challenged by cisplatin. Disruption of E-cadherin increased apoptosis and necroptosis while activating inflammatory response in cisplatin-treated tubular epithelial cells. Restoration of E-cadherin by administration of PPBICA protected against cisplatin-induced injury both in vivo and in vitro via inhibiting renal inflammation and programmed cell death (Shown in Fig. 10 ). E-cadherin is a key adherent protein in the formation of adhesion junctions, which are critical to tubule integrity in normal kidney. E-cadherin has been extensively investigated in regulating phenotype of tubular epithelial cells via EMT in the kidney field. Not surprisingly, E-cadherin deficiency has been found in several types of cancers [15] . In fact, evidence shows that reduced E-cadherin is correlated with β-catenin expression and poor prognosis of renal RCC; and, E-cadherin prevents β-catenin translocation from membrane to cytoplasm, suppressing wnt/β-catenin signaling [16] . A recent study showed that inhibition of E-cadherin-α/E-catenin complex by miR-720 promoted RCC [17] , indicating a preventive role of E-cadherin in RCC. In the fibrotic kidney, loss of E-cadherin, which is a marker for epithelial cells, and gain of α-SMA expression, the marker Fig. 6 PPBICA restored E-cadherin level and prevented cisplatininduced acute kidney injury in mice. a, b Immunohistochemistry and western blot analysis of E-cadherin in mice. PPBICA upregulated E-cadherin in cisplatin-treated mice. c PAS staining. Histological analysis shows PPBICA reduced tubular necrosis, dilation and cast formation in cisplatin nephropathy. d, e Serum creatinine and blood urea nitrogen. PPBICA improved renal function in cisplatin nephropathy. f-h Western blot, real-time PCR, and immunohistochemistry analysis of KIM1. PPBICA attenuated cisplatin-induced upregulation of KIM1 protein and mRNA. Data represent the mean ± SEM for 6-8 mice. * p < 0.05, * * p < 0.01, * * * p < 0.001 compared with control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared with model. IHC immunohistochemistry, Cis cisplatin for myofibroblasts, is a key process in myofibroblast transdifferentiation from epithelial origin [18] . Although the concept that activated myofibroblasts are mainly derived from epithelial cells is challenged, new data show that dedifferentiated tubular epithelial cells engage a profibrotic gene expression. This drives interstitial fibrosis without completely transiting to α-SMA + myofibroblasts [19, 20] . This data support the important role of E-cadherin in renal fibrosis. However, the detailed function of E-cadherin in acute injury of kidney cells has not been fully understood. We found that E-cadherin expression was substantially reduced by cisplatin in proximal tubular cells in vivo and in vitro. Knockdown of E-cadherin enhanced the production of kidney injury marker KIM1, but restoration of E-cadherin by PPBICA effectively suppressed KIM1 expression, and reduced cisplatin-induced programmed cell death. These results are consistent with recent finding that pharmacological inhibition of Src kinase prevented the degradation of several adherens and tight junction proteins, which includes E-cadherin, ZO-1 and claudins, in the I/R kidney, and oxidative stress-challenged renal tubular epithelial cells [6] . Additionally, we found that PPBICA did not further protect against renal injury in absence of E-cadherin, indicating PPBICA functions specifically via an E-cadherin-dependent mode.
The mechanisms by which PPBICA prevents cisplatininduced nephrotoxicity were then evaluated. PPBICA not only limited programmed cell death induced by TNF-α and TNF-α plus z-VAD, but also prevented cisplatin-induced necroptosis and apoptosis. Our previous study showed that cisplatin induced the activation of caspase3-dependent apoptosis and RIPK-mediated necroptosis of tubular epithelial cells [2, 21, 22] . This may lead to loss of tubular epithelial cells and tubule integrity, where adherent junctions are further damaged, back-leaking of tubular fluid and inflammatory responses accelerated, which causes renal dysfunction. However, when the E-cadherin was restored, tubular epithelial cells showed resistance to cisplatin and the cell viability was upregulated. RIPK1/RIPK3 axis activation and cleavage of caspase3 were also inhibited. Additionally, PPBICA attenuated cisplatin-induced inflammatory response, which was evidenced by reduced production of proinflammatory cytokines including TNF-α, IL-1β, IL-6, MCP-1, and NF-κB. Regarding underlying mechanisms, we offer the following explanations. First, PPBICA-mediated restoration of E-cadherin may recover the tubule integrity while limiting back-leak of tubular fluid and subsequent inflammatory response. Second, proximal tubular cells succumb to necroptosis release damageassociated molecular patterns (DAMPs) including highmobility group box 1 (HMGB1), heat-shock proteins, uric acid, and IL-33. These may activate inflammation-related signaling pathways, such as Toll-like receptors, and form feedback loops of inflammatory response called necroinflammation [23, 24] . In this setting, the anti-necroptotic effects of PPBICA may also contribute to the attenuation of renal inflammation. Third, we know overexpression of E-cadherin, which is highly induced in alternatively activated macrophages (M2), suppresses inflammatory response in macrophages, indicating the novel function of E-cadherin in immune cells [25] . In this setting, the regulative role of E-cadherin on macrophage infiltration and ratio of M2/M1 cells may be also responsible for antiinflammatory effect of PPBICA in treatment of AKI. Additionally, we detected whether PPBICA limited kidney damage by affecting the cellular uptake of cisplatin. Organic cation transporters-2 (OCT2) is well accepted as a critical transporter in mediating the absorption of cisplatin. In the current study, we found PPBICA did not alter OCT2 expression, indicating PPBICA may function through an OCT-independent mechanism [26] .
Importantly, by designing both prevention and treatment studies, we evaluated the E-cadherin-targeted therapy in cisplatin nephropathy by peritoneal injection of PPBICA. Results showed that PPBICA restored E-cadherin expression in injured kidney. Consequently, it prevented the decline of renal function and cell damage, which may be correlated with its inhibitory roles on NF-κB-driven renal inflammation and RIPK-mediated programmed cell death. Finally, it is important to note that PPBICA also has protective effects in kidney injury in established AKI models.
In conclusion, E-cadherin has fundamental and functional roles in controlling tubule integrity, programmed cell death, and renal inflammation. In this regard, restoration of E-cadherin by PPBICA should be considered as a novel therapeutic strategy for acute kidney injury.
